Leonard Post, Ph.D. has served as a member of our Board since 2018 and as our lead independent director since 2024. Dr. Post has over three decades of pharmaceutical R&D experience. From July 2016 to January 2024, Dr. Post served as Chief Scientific Officer of Vivace Therapeutics, an oncology company working on small molecules targeting the hippo pathway, and from October 2018 to January 2024 served as Chief Scientific Officer of its sister company Virtuoso Therapeutics, a company working on bispecific antibodies for oncology. From February 2010 until June 2016, Dr. Post worked at BioMarin, in various positions including Chief Scientific Officer. During that time, he oversaw the initiation of BioMarin's first gene therapy project for hemophilia A. Prior to that, Dr. Post served as Chief Scientific Officer of LEAD Therapeutics, Senior Vice President of Research & Development at Onyx Pharmaceuticals, and Vice President of Discovery Research at Parke-Davis Pharmaceuticals. Dr. Post is also currently an advisor to Canaan Partners. Dr. Post has served on the board of directors of publicly-traded biopharmaceutical company uniQure N.V. (Nasdaq: QURE) since June 2020, where he serves as chair of its research and development committee, and privately-held companies, Orphagen Pharmaceuticals, Inc., Fedora Pharma, Inc., ImmvirX, ML Biosolutions, Grace Science LLC and Acelink Therapeutics. Dr. Post also previously served on the board of directors of publicly-traded Fulgent Genetics, Inc. (Nasdaq: FLGT) from August 2022 to October 2022. Dr. Post is a virologist by training and did early work on engineering of herpes simplex virus as a postdoctoral fellow. He has a Bachelor of Science degree in Chemistry from University of Michigan, and a Ph.D. in Biochemistry from University of Wisconsin. Dr. Post's extensive experience in the biotechnology industry, and specifically in oncolytic viruses, contributed to our Board's conclusion that he should serve as a director of our Company.